Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia

Current Medical Research and Opinion

Volumn 20, Issue 1, 2004, Pages 13-18

  Lukacsko, P ^a   Walters, E J ^a   Cullen, E I ^a   Niecestro, R ^a   Friedhoff, L T ^a  

^a Andrx Laboratories Inc   (United States)

Author keywords

Cholesterol, low density lipoprotein; Efficacy; Hypercholesterolemia; LDL C lowering; Lovastatin, extended release

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BODY MASS; BRAIN ISCHEMIA; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON BILE DUCT STONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; FEMALE; GALLSTONE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KNEE PAIN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; UTERUS MYOMA;

ADULT; AGED; ANESTHETICS, LOCAL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0346724648     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002612     Document Type: Article

References (11)

1. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: the Framingham Study. Arch Intern Med 1981;14:1128-31
2. The Scandanavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
3. Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
5. Assmann G, Schulte H. European lipid guidelines: therapeutic recommendations. European Atherosclerosis Society. Am J Cardiol 1989;63:53-55H
6. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9
7. McClelland GA, Stubbs RJ, Fix JA, Pogany SA, Zentner GM. Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharm Res 1991;8:873-6
8. Sun JX, Niecestro R, Phillips G, et al. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in human. J Clin Pharmacol 2002;42:198-204
9. Davidson MH, Lukacsko P, Sun JX, et al. A multiple-dose pharmacokinetic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther 2002;24:112-25
10. Downs JR, Clearfield M, Weis, S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22
11. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7